Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...

GuruFocus.com11-01

Revenue: $9 million in net Pyrukynd revenue for Q3 2024, a 22% increase compared to Q3 2023. Cash Position: Approximately $1.7 billion in cash and investments at the end of Q3 2024. Milestone Payments...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2480201760?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BEiT2TttpVN.QEvEptyIpA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/b49f881031f5edba4200c26f78a0f1fb","is_english":true,"pubTime":"2024-11-01 15:03","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2480201760","market":"us","top_or_hot":-1,"title":"Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...","media":"GuruFocus.com","content":"<div>\n<p>Revenue: $9 million in net Pyrukynd revenue for Q3 2024, a 22% increase compared to Q3 2023.\nCash Position: Approximately $1.7 billion in cash and investments at the end of Q3 2024.\nMilestone Payments...</p>\n\n<a href=\"https://finance.yahoo.com/news/agios-pharmaceuticals-inc-agio-q3-070330912.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-01 15:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/agios-pharmaceuticals-inc-agio-q3-070330912.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Revenue: $9 million in net Pyrukynd revenue for Q3 2024, a 22% increase compared to Q3 2023.\nCash Position: Approximately $1.7 billion in cash and investments at the end of Q3 2024.\nMilestone Payments...</p>\n\n<a href=\"https://finance.yahoo.com/news/agios-pharmaceuticals-inc-agio-q3-070330912.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGIO","symbol_name":"Agios Pharmaceuticals, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/agios-pharmaceuticals-inc-agio-q3-070330912.html","article_id":"2480201760","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BEiT2TttpVN.QEvEptyIpA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/b49f881031f5edba4200c26f78a0f1fb"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480201760","pubTimestamp":1730444610,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Revenue: $9 million in net Pyrukynd revenue for Q3 2024, a 22% increase compared to Q3 2023.Cash Position: Approximately $1.7 billion in cash and investments at the end of Q3 2024.Milestone Payments: Received $1.1 billion following FDA approval of vorasidenib.R&D Expenses: $72.5 million for Q3 2024, a decrease of $9.4 million from Q3 2023.SG&A Expenses: $38.5 million for Q3 2024, an increase of $12.7 million from Q3 2023.Cost of Sales: $0.8 million for Q3 2024.Patient Enrollment: 211 patients completed prescription enrollment for Pyrukynd, with 127 net patients on therapy.GuruFocus has detected 5 Warning Signs with AGIO.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Agios Pharmaceuticals Inc  received $1.1 billion in milestone payments following FDA approval of vorasidenib, strengthening its cash position.The company received FDA orphan drug designation for Tebapivat for the treatment of myelodysplastic syndromes , highlighting its p","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"AGIO":"Agios Pharmaceuticals, Inc."},"translate_title":"Agios Pharmaceuticals Inc(AGIO)2024年第三季度收益看涨期权亮点：强劲的现金状况和……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGIO":1},"content_text":"Revenue: $9 million in net Pyrukynd revenue for Q3 2024, a 22% increase compared to Q3 2023.\nCash Position: Approximately $1.7 billion in cash and investments at the end of Q3 2024.\nMilestone Payments: Received $1.1 billion following FDA approval of vorasidenib.\nR&D Expenses: $72.5 million for Q3 2024, a decrease of $9.4 million from Q3 2023.\nSG&A Expenses: $38.5 million for Q3 2024, an increase of $12.7 million from Q3 2023.\nCost of Sales: $0.8 million for Q3 2024.\nPatient Enrollment: 211 patients completed prescription enrollment for Pyrukynd, with 127 net patients on therapy.\n\n\nWarning! GuruFocus has detected 5 Warning Signs with AGIO.\n\nRelease Date: October 31, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nAgios Pharmaceuticals Inc (NASDAQ:AGIO) received $1.1 billion in milestone payments following FDA approval of vorasidenib, strengthening its cash position.\nPositive Phase 3 data for Mitapivat in Thalassemia and Pyruvate Kinase Deficiency (PKD) were reported, supporting potential future launches.\nThe company completed enrollment for the Phase 3 rise up study for sickle cell disease, demonstrating strong execution and community trust.\nAgios Pharmaceuticals Inc (NASDAQ:AGIO) has a strong cash position with approximately $1.7 billion, enabling financial independence for future launches and pipeline expansion.\nThe company received FDA orphan drug designation for Tebapivat for the treatment of myelodysplastic syndromes (MDS), highlighting its potential in addressing unmet needs.\n\n Negative Points \n\nThe Phase 3 activate study of Mitapivat in children with PK deficiency did not meet the prespecified statistical criterion for the primary endpoint.\nThere are concerns about the regulatory environment for sickle cell disease treatments following the withdrawal of Oxbryta, which may impact future approvals.\nThe company faces challenges in educating payers about the unmet need and clinical profile of Mitapivat for thalassemia.\nAgios Pharmaceuticals Inc (NASDAQ:AGIO) is operating in a competitive landscape with other companies also targeting sickle cell disease and MDS.\nThe company must navigate complex market access and regulatory pathways, particularly in international markets like the GCC region.\n\n Q & A Highlights \nQ: How is Agios Pharmaceuticals thinking about capital allocation and business development now that vorasidenib has been monetized? A: Cecilia Jones, CFO, explained that Agios is proud of its strong balance sheet and will prioritize potential launches for Mitapivat in thalassemia and sickle cell disease, advancing the pipeline, and expanding it both internally and externally. The company remains disciplined in its approach, focusing on rare, transformative opportunities with a clear regulatory path and value creation for shareholders.\nQ: What are the expectations for the Phase 3 portion of the Rise Up trial for sickle cell disease? A: Sarah Gheuens, Chief Medical Officer, stated that the Phase 3 trial has two primary endpoints: hemoglobin response and sickle cell pain crisis reduction. Both endpoints are powered to detect a difference with 90% or more confidence. The goal is to deliver a drug that addresses both hemolytic anemia and vaso-occlusion improvements.\nQ: Can you discuss the primary endpoints in the Rise Up study and whether success on just one endpoint could support a regulatory filing? A: Sarah Gheuens explained that while the study has two primary endpoints, if only one is met, there is an opportunity to transfer alpha to secondary endpoint testing, such as fatigue. The regulatory approval will depend on the overall benefit-risk profile as assessed by regulators.\nQ: How is Agios addressing potential mistrust in the sickle cell community following the withdrawal of Oxbryta? A: Brian Goff, CEO, emphasized the importance of maintaining high engagement with the sickle cell community. Agios involves community members in trial design and recruitment, ensuring their input is reflected in the process. The company remains committed to listening and addressing the community's concerns.\nQ: What are the plans for the pediatric trials in thalassemia following the PKD kids trial data? A: Sarah Gheuens indicated that Agios will take a similar approach to the PKD pediatric trial, leveraging the benefit-risk profile established in adult thalassemia patients. More details on timing and design will be shared at a later date.\nQ: How quickly could payer access come online for the thalassemia launch, and are payers aware of Mitapivat's clinical profile? A: Tsveta Milanova, Chief Commercial Officer, noted that the market access team is already engaging with payers on disease state education. While awareness is currently low, the team is preparing for launch and expects to achieve strong access outcomes similar to those in PK deficiency.\nQ: What additional data should be expected from the Energize T readout beyond the top-line results? A: Sarah Gheuens mentioned that the full readout will include an intent-to-treat analysis, details on key secondary endpoints, and a safety overview. The company hopes to present the data at an upcoming medical meeting, with Ash being a potential venue.\nQ: Can you provide details on the baseline VOCs for the sickle cell disease trial and the timing for Tebapivat Phase 2B data? A: Sarah Gheuens stated that baseline characteristics will be presented with the full data readout. For Tebapivat, more details on timing and data from the Phase 2B trial will be shared next year.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2480201760"}